Triquilar ED may be available in the countries listed below.
Ethinylestradiol is reported as an ingredient of Triquilar ED in the following countries:
Levonorgestrel is reported as an ingredient of Triquilar ED in the following countries:
International Drug Name Search
Tildren may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Tiludronic Acid is reported as an ingredient of Tildren in the following countries:
Tiludronic Acid disodium salt (a derivative of Tiludronic Acid) is reported as an ingredient of Tildren in the following countries:
International Drug Name Search
Peridom may be available in the countries listed below.
Domperidone maleate (a derivative of Domperidone) is reported as an ingredient of Peridom in the following countries:
International Drug Name Search
Solucion Bicarbonato de Sodio may be available in the countries listed below.
Sodium Bicarbonate is reported as an ingredient of Solucion Bicarbonato de Sodio in the following countries:
International Drug Name Search
Formicina may be available in the countries listed below.
Lincomycin hydrochloride monohydrate (a derivative of Lincomycin) is reported as an ingredient of Formicina in the following countries:
International Drug Name Search
Rienton may be available in the countries listed below.
Carteolol hydrochloride (a derivative of Carteolol) is reported as an ingredient of Rienton in the following countries:
International Drug Name Search
Amiogamma may be available in the countries listed below.
Amiodarone hydrochloride (a derivative of Amiodarone) is reported as an ingredient of Amiogamma in the following countries:
International Drug Name Search
Kornam may be available in the countries listed below.
Terazosin is reported as an ingredient of Kornam in the following countries:
Terazosin hydrochloride (a derivative of Terazosin) is reported as an ingredient of Kornam in the following countries:
International Drug Name Search
Calcilac may be available in the countries listed below.
Calcium Carbonate is reported as an ingredient of Calcilac in the following countries:
Colecalciferol is reported as an ingredient of Calcilac in the following countries:
International Drug Name Search
Depixol may be available in the countries listed below.
UK matches:
Flupentixol decanoate (a derivative of Flupentixol) is reported as an ingredient of Depixol in the following countries:
Flupentixol dihydrochloride (a derivative of Flupentixol) is reported as an ingredient of Depixol in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Vercure may be available in the countries listed below.
Betahistine dimesilate (a derivative of Betahistine) is reported as an ingredient of Vercure in the following countries:
International Drug Name Search
Tioside may be available in the countries listed below.
Thiocolchicoside is reported as an ingredient of Tioside in the following countries:
International Drug Name Search
Brudifen may be available in the countries listed below.
Diphenhydramine hydrochloride (a derivative of Diphenhydramine) is reported as an ingredient of Brudifen in the following countries:
International Drug Name Search
Doxepin Hydrochloride (BANM, USAN) is known as Doxepin in the US.
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| USAN | United States Adopted Name |
Rx only
Diphenhydramine hydrochloride is an antihistamine drug having the chemical name 2-(Diphenylmethoxy)-N,N-dimethylethylamine hydrochloride. It occurs as a white, crystalline powder, is freely soluble in water and alcohol.
The structural formula is as follows:
C17H21NO•HCl M.W. 291.82
Diphenhydramine hydrochloride in the parenteral form is a sterile, pyrogen-free solution available in a concentration of 50 mg of diphenhydramine hydrochloride per mL. pH 4.0 to 6.5; sodium hydroxide and/or hydrochloric acid added, if needed, for pH adjustment.
Diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells.
Diphenhydramine hydrochloride in the injectable form has a rapid onset of action. Diphenhydramine hydrochloride is widely distributed throughout the body, including the CNS. A portion of the drug is excreted unchanged in the urine, while the rest is metabolized via the liver. Detailed information on the pharmacokinetics of diphenhydramine hydrochloride injection is not available.
Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical.
For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated.
For active treatment of motion sickness.
For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents.
This drug should not be used in neonates or premature infants.
Because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.
Because of the risk of local necrosis, this drug should not be used as a local anesthetic. Antihistamines are also contraindicated in the following conditions: Hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure.
Antihistamines should be used with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction.
Local necrosis has been associated with the use of subcutaneous or intradermal use of intravenous diphenhydramine hydrochloride.
In pediatric patients, especially, antihistamines in overdosage may cause hallucinations, convulsions, or death.
As in adults, antihistamines may diminish mental alertness in pediatric patients. In the young pediatric patient, particularly, they may produce excitation.
Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.
Diphenhydramine hydrochloride has an atropine-like action and, therefore, should be used with caution in patients with a history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease or hypertension. Use with caution in patients with lower respiratory disease including asthma.
Patients taking diphenhydramine hydrochloride should be advised that this drug may cause drowsiness and has an additive effect with alcohol.
Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc.
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.).
MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.
Long-term studies in animals to determine mutagenic and carcinogenic potential have not been performed.
Pregnancy Category B. Reproduction studies have been performed in rats and rabbits at doses up to 5 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to diphenhydramine hydrochloride. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Diphenhydramine hydrochloride should not be used in neonates and premature infants (see CONTRAINDICATIONS).
Diphenhydramine hydrochloride may diminish mental alertness, or, in the young pediatric patient, cause excitation. Overdosage may cause hallucinations, convulsions, or death (see WARNINGS and OVERDOSAGE).
See also DOSAGE AND ADMINISTRATION section.
The most frequent adverse reactions are underscored.
Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in pediatric patients. Atropine-like signs and symptoms; dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur.
Stimulants should not be used.
Vasopressors may be used to treat hypotension.
THIS PRODUCT IS FOR INTRAVENOUS OR INTRAMUSCULAR ADMINISTRATION ONLY.
Diphenhydramine hydrochloride in the injectable form is indicated when the oral form is impractical.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.
Pediatric Patients, other than premature infants and neonates: 5 mg/kg/24 hr or 150 mg/m2/24 hr. Maximum daily dosage is 300 mg. Divide into four doses, administered intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly.
Adults: 10 to 50 mg intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly, 100 mg if required; maximum daily dosage is 400 mg.
DiphenhydrAMINE Hydrochloride Injection, USP in parenteral form is supplied as:
Product No. | NDC No. | Strength | Volume |
660401 | 63323-664-01 | 50 mg/mL | 1 mL fill in a 2 mL vial. |
It is supplied as a sterile, pyrogen-free solution containing 50 mg diphenhydramine hydrochloride in each milliliter of solution, and available in packages of 25.
Vial stoppers do not contain natural rubber latex.
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Protect from freezing and light.
45954C
Revised: April 2008
PACKAGE LABEL - PRINCIPAL DISPLAY - Diphenhydramine HCl 1 mL Single Dose Vial Label
NDC 63323-664-01
660401
DIPHENHYDRAMINE HCl INJECTION, USP
50 mg/mL
High Potency
For IM or IV Use
Protect from freezing and light.
1 mL in a 2 mL Single Dose Vial
PACKAGE LABEL - PRINCIPAL DISPLAY - Diphenhydramine Hydrochloride 1 mL Single Dose Tray Label
NDC 63323-664-01
660401
DIPHENHYDRAMINE HYDROCHLORIDE INJECTION, USP
50 mg/mL
High Potency
For IM or IV Use Rx only
1 mL in a 2 mL Single Dose Vial
| DIPHENHYDRAMINE diphenhydramine hydrochloride injection, solution | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA040466 | 08/01/2002 | |
| Labeler - APP Pharmaceuticals, LLC (608775388) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| APP Pharmaceuticals, LLC | 840771732 | MANUFACTURE | |
Alsartan may be available in the countries listed below.
Valsartan is reported as an ingredient of Alsartan in the following countries:
International Drug Name Search
Naftilan may be available in the countries listed below.
Fenofibrate is reported as an ingredient of Naftilan in the following countries:
International Drug Name Search
Definition of Cystinuria: Cystinuria is a disorder characterized by stones in the kidney, ureter, and bladder. It is caused by excessive excretion of certain amino acids (protein building blocks) because of genetic abnormality. (See also nephrolithiasis).
The following drugs and medications are in some way related to, or used in the treatment of Cystinuria. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Medical Encyclopedia:
